Bromide

Bromide

SCHEMBL1177352

Br.NCC(=O)CC(Cc1ccccc1)C(=O)O

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CPA1 P15085 10/20 0.68
CPA3 P15088 3/20 0.66
CPB1 P15086 1/20 0.66
CPB2 Q96IY4 1/20 0.66
CYP1A2 P05177 1/20 0.63
MME P08473 1/20 0.57
FOLH1 Q04609 1/20 0.56
SLC1A3 P43003 1/20 0.56
SLC1A2 P43004 1/20 0.56
SLC1A1 P43005 1/20 0.56
ANPEP P15144 1/20 0.54
RNPEP Q9H4A4 1/20 0.54
DNPEP Q9ULA0 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1177225 0.98 CPA1 (0.70) CPA1CPA3CPB1CPB2CYP1A2
SCHEMBL17948789 0.98 CPA1 (0.70) CPA1CPA3CPB1CPB2CYP1A2
SCHEMBL17799165 0.86 CPA1 (0.72) CPA1CPA3CPB1CPB2CYP1A2
SCHEMBL28102506 0.81 CPA1 (1.00) CPA1CPA3CPB1CPB2CYP1A2
SCHEMBL7286643 0.81 CPA1 (0.70) CPA1CPA3CPB1CPB2CYP1A2
SCHEMBL6469019 0.81 CPA1 (0.70) CPA1CPA3CPB1CPB2CYP1A2
SCHEMBL10076047 0.81 CPA1 (0.70) CPA1CPA3CPB1CPB2CYP1A2
SCHEMBL28484063 0.81 CPA1 (0.70) CPA1CPA3CPB1CPB2CYP1A2
SCHEMBL9029155 0.80 CPA1 (0.72) CPA1CPA3CPB1CPB2CYP1A2
SCHEMBL1915564 0.80 CPA1 (1.00) CPA1CPA3CPB1CPB2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8692014-B2 Acid addition salts of 5-aminolevulinic acid or its derivatives PHOTOCURE ASA (NO) 2014-04-08 US disclosed
US-20110125012-A1 ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES BRAENDEN JON ERIK 2011-05-26 US disclosed
EP-2308830-A1 Acid addition salts of 5-aminolevulinic acid or its derivatives Photocure ASA (NO) 2011-04-13 EP disclosed
US-7888526-B2 Nonhygroscopic photosensitizing agents; sulphonate, hydrobromide, sulfate, nitrate and/or phosphate derivatives; diagnosing skin disorders PHOTOCURE ASA (NO) 2011-02-15 US disclosed
US-20080064752-A1 Acid Addition Salts Of-5-Aminolevulinic Acid Or Its Derivatives PHOTOCURE ASA (NO) 2008-03-13 US disclosed
EP-1727786-A1 ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES Photocure ASA (NO) 2006-12-06 EP disclosed
WO-2005092838-A1 ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES PHOTOCURE ASA (NO) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064752-A1 Acid Addition Salts Of-5-Aminolevulinic Acid Or Its Derivatives ALAD, AASDHPPT, ABAT CPA1 2423/4885CPA3 3029/4885CPB1 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.